> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# DaVita's China Unit Has Zero Valuation Cushion After A $62 Million Impairment
- URL: https://www.bullished.co/davitas-china-unit-has-zero-valuation-cushion-after-a-62-million-impairment-bf7a804f/
- Published: 2026-10-29T21:11:42.000Z
- Updated: 2026-10-29T21:11:42.000Z
- Description: The dialysis giant's quarterly report lists China as its only reporting unit still at risk, a quarter after naming none.
- Author: Matteo Parrino
- Tags: SEC Filings, DVA, Industry: Healthcare

DaVita, which runs kidney dialysis centers, recorded a [$62 million impairment](https://www.sec.gov/Archives/edgar/data/0000927066/000092706626000134/dva-20260930.htm?ref=bullished.co) on its China business in the third quarter, and its 10-Q filed Thursday shows the unit now has no cushion between its estimated value and its carrying amount. The [prior quarter's report](https://www.sec.gov/Archives/edgar/data/0000927066/000092706626000108/dva-20260630.htm?ref=bullished.co) had indicated no impairment and no reporting unit at risk of a significant goodwill charge.

## A cushion of zero

The 10-Q lists China as the only reporting unit still at risk. It carries $42,930 thousand of goodwill, and its carrying-amount coverage, meaning the excess of estimated fair value over book value, is zero percent.

The filing gives two sensitivities. A 100 basis point rise in the discount rate, a full percentage point, would cut the unit's estimated value 9.6%. Operating income that stayed 300 basis points lower over the long term would trim it 2.2%.

DaVita warns that China could see more goodwill charges if patient census, operating margins, reimbursement rates or expected cash flows shift further.

## Reimbursement cuts behind the charge

DaVita blames lower reimbursement rates for the write-down.

The goodwill portion was $57,104 thousand, of which $31,597 thousand was allocated to noncontrolling interests. Accumulated goodwill impairment in the ancillary services segment now stands at $209,955 thousand, up from $153,403 thousand at the end of June.

The company's [earnings release](https://www.sec.gov/Archives/edgar/data/0000927066/000092706626000132/dva93026ex991.htm?ref=bullished.co) says the effect on net income attributable to DaVita was $27 million, after a $1 million tax benefit and a $34 million noncontrolling interest credit. DaVita calls the charge non-cash and strips it out of its adjusted measures: operating income was $499 million, or $561 million adjusted.

## The international growth engine stumbles

DaVita's U.S. dialysis business, its core, treated about 200,500 patients at 2,657 centers at the end of 2025, according to its annual report. Abroad, it ran 598 centers in 14 countries as of September 30, 2026.

International revenue rose 18.1% to $1,156 million over the first nine months. Reported international operating income fell to $40 million from $93 million a year earlier, with the China charge the difference. On the company's adjusted measure it rose to $102 million.

DaVita's market value was $11.7 billion at Thursday's report.

The company's annual impairment testing, which it runs at various points through the year, and its next 10-Q will show whether the unit with no cushion takes further charges.

### Sources

- [10-Q Filing — DaVita Inc. (DVA)](https://www.sec.gov/Archives/edgar/data/0000927066/000092706626000134/dva-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — DaVita Inc. (DVA), Q2 FY2026 filed 2026-08-04 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000927066/000092706626000108/dva-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, dva93026ex991.htm) — DaVita Inc., filed 2026-10-29](https://www.sec.gov/Archives/edgar/data/0000927066/000092706626000132/dva93026ex991.htm?ref=bullished.co) — SEC EDGAR
- [DaVita Non-GAAP EPS of $3.82 beats by $0.25, revenue of $3.57B beats by $50M (DVA:NYSE) | Seeking Alpha](https://seekingalpha.com/news/4660759-davita-non-gaap-eps-of-3%5F82-beats-by-0%5F25-revenue-of-3%5F57b-beats-by-50m?ref=bullished.co) — seekingalpha.com
- [Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?](https://finance.yahoo.com/healthcare/articles/davitas-q3-earnings-reflect-improving-152800109.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [DaVita (DVA) Has The Market Looking Again, What Is Behind The Attention?](https://finance.yahoo.com/healthcare/articles/davita-dva-market-looking-again-081116208.html?ref=bullished.co) — Yahoo Finance
- [Is DaVita (DVA) Still Reasonable After Its 139% Three Year Run?](https://finance.yahoo.com/markets/stocks/articles/davita-dva-still-reasonable-139-001300544.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [How Investors Are Reacting To DaVita (DVA) Kidney Week Research Push](https://finance.yahoo.com/healthcare/articles/investors-reacting-davita-dva-kidney-051057066.html?ref=bullished.co) — Yahoo Finance